Sai Chavala, MD
Retina Specialist · Mount Pleasant, TXNPI 1548391311
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Onmark, Inc. at 51.7% of the total. Reporting peaked in 2024 at $7,740 and has fallen 79.1% since, to $1,621 in 2025.
Across 54 payments — averaging $219.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Onmark, Inc.$6K
- Eyepoint US, Inc.$2K
- Cardinal Health 108 LLC$2K
- Apellis Pharmaceuticals, Inc.$596
- Regeneron Healthcare Solutions, Inc.$252
- Biotissue Holdings Inc.$236
- plus $885 from 9 others
Across 25 payments — averaging $2047.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$37K
- Astellas Pharma Global Development$11K
- Alcon Research LLC$3K
What the payments were for
- Consulting fees$6,51555%
- Travel & lodging$2,50221%
- Food & beverage$2,81624%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Onmark, Inc. | 10 | $6,124 |
| Eyepoint US, Inc. | 6 | $2,185 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Apellis Pharmaceuticals, Inc. | 6 | $596 |
| Regeneron Healthcare Solutions, Inc. | 6 | $252 |
| Biotissue Holdings Inc. | 5 | $236 |
| Novartis | 4 | $206 |
| Regeneron | 2 | $195 |
| AbbVie(2 entities) | 5 | $188 |
| Astellas Pharma US Inc | 4 | $108 |
| ANI Pharmaceuticals, Inc. | 1 | $82 |
| Kala Pharmaceuticals, Inc. | 1 | $38 |
| Genentech USA, Inc. | 1 | $32 |
| Notal Vision, Inc. | 1 | $22 |
| Alcon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,854 in reported general payments places this provider in the 80th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 77 | $4,551 |
| Brimonidine Tartrate | 49 | $1,880 |
| MoxifloxacinMoxifloxacin Hcl | 47 | $1,113 |
| Timolol Maleate | 40 | $863 |
| Dorzolamide Hcl | 17 | $217 |
| Latanoprost | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Mount Pleasant
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
- Emmanuel ChangBellaire$254K
- Ting Fang SuarezBellaire$156K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
- Garvin DavisHouston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.